| Peer-Reviewed

Kidney Tumors in Adult: Epidemiological, Clinical, Histopathological, Therapeutic and Progressive Aspects

Received: 6 May 2020     Accepted: 25 May 2020     Published: 8 June 2020
Views:       Downloads:
Abstract

Objective: To study the epidemiological, diagnostic and therapeutic profile of kidney tumors in adults over the past five years. Patients and methods: This was a retrospective, descriptive and analytical Study from the 1st of January 2014 to 31st of December 2018. All patients aged 18 years or older hospitalized, followed or operated in the service for a kidney tumor were included in the serie. The parameters studied were: epidemiological, clinical and paraclinical aspects, TNM stage (2017), treatment, histological type, evolution and survival. The calculation of survival rate was done with SPSS IBM statistics 24. Results: sixty-seven patients were included. The average annual incidence was 13. The average age of the patients was 49.6±15.6 years. The sex-ratio was 1.2. Hypertension, smoking and obesity were the main risk factors found. The average size of the tumor was 7.7±4.40 cm. The left kidney location was more frequent. Thirteen patients (20%) had a localized tumor in the kidney, twenty patients (31%) had locally advanced cancer and thirty two patients (49%) had metastasized cancer. Forty-seven patients (70%) had surgical treatment, including five patients with an anti-angiogenic adjuvant therapy. Twelve (17.9%) patients had an anti-angiogenic therapy only. Clear cell carcinoma was the most common histology type. The overall survival (OS) rate for cancer patients at 2 years was 22% for surgical treatment, 8% for medical treatment. Conclusion: this work reveals that adult kidney cancer affects young adult and is discovered at advanced stages without any significant change in the epidemiological and clinical profile of these cancers during the two decades.

Published in International Journal of Clinical Urology (Volume 4, Issue 2)
DOI 10.11648/j.ijcu.20200402.11
Page(s) 39-44
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2020. Published by Science Publishing Group

Keywords

Tumor, Cancer, Kidney, Nephrectomy, Anti-angiogenic

References
[1] Coulange C, Rambeaud J J. Cancer du rein de l’adulte Rapport-Congrès AFU 1997. Prog Urol 1997; 5.
[2] Honde M, Koffi K, Ette-dieng E, Boka MB, Effi B A, Troh E et al. Aspects épidémiologie et caractéristiques histologies du cancer du rein de l’adulte A ABIDJAN - COTE D’IVOIRE Méd Afr Noire; 1998, 45: 449-450.
[3] Lopez-Beltran A, Scarpelli M, Montironi R, Kirkali Z. WHO classification of the renal tumors of the adults. Eur Urol 2006; 49: 798-805.
[4] Reaume M N, Basappa N S, Wood L, Kapoor A, Bjarnason G A, Blais N, et al. Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017. Can Urol Asso Journal. 2017; 11 (10): 310-20.
[5] Skolarus T A, Serrano M F, Grubb R L, Katz M D, Bullock T L Effect of reclassification on the incidence of benign and malignant renal tumors. J Uro 2010; 183: 455-459
[6] Fall B, Diao B, Sow Y, Sarr A, Thiam A, Fall P A et al. Le cancer du rein de l’adulte au Sénégal: aspects épidémiologiques et cliniques actuels et évolution du profil sur les deux dernières décennies. Prog urol 2011; 21: 521—526.
[7] Bowa K, Kachimba J S, Labib M A, Mudenda V, Chikwenya M. The Pattern of Urological Cancers in Zambia. AFJU. 2009; 15 (2): 84-87.
[8] Benjelloun M, Nouri A, Ghannam Y, Karmouni T, El Khader K, Koutani A et al. Le cancer du rein chez l’adulte. Etude rétrospective à propos de 155 cas. AFJU. 2009; 15 (4): 268-277.
[9] Lynch C F, Cohen M B. Urinary system. Cancer 1995; 75 (1): 316-329.
[10] Muscat J E, Hoffmann D, Wynder E L. The epidemiology of renal cell carcinoma. A second look. Cancer. 1995; 75 (10): 2552-2557.
[11] Black R J, Bray F, Ferlay J, Parkin D M. Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer 1977; 33: 1075–1107.
[12] Ouattara A, Hodonou R, Avakoudjo J, Cisse D, Zango B, Gandaho B et al. Épidémiologie des cancers urologiques au Centre national hospitalier universitaire Hubert Koutoukou Maga Cotonou, Bénin. Analyse d’une série hospitalière de 158 cas. Prog Urol 2012; 22 (5): 261-265.
[13] Soulié M, Coloby P, Irani J, Lebret T, Patard J J, Pfister C et al. Recommandations de bonnes pratiques cliniques 2013 du CCAFU: Diagnostic, traitement et suivi des cancers urologiques chez l’homme et la femme. Prog Urol. 2013; 23 (2): 51-54.
[14] Argani P, Perlman E J, Breslow N E, Browning N E, Green D M, D’Anngio G J et al. Clear cell sarcoma of the kidney: a review of 351 cases from the National Wilms Tumor Study Group Pathology Centre. Am. J. Surg. Pathol. 2000; 24: 4-18.
[15] Bouya P A, Lomina D. Diagnostic du cancer du rein de l'adulte. Carcinologie Pratique en Afrique 2004; 6 (1): 6-18.
[16] Motzer R J, Hutson T E, Tomczak P, Michaelson M D, Bukowski R M, Rixe O et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356 (2): 115-124.
[17] Flohr H, Breull W. Effect of etafenone on total and regional myocardial blood flow. Arzneimittelforschung. 1975; 25 (9): 1400-1403.
[18] Helenon O, Denys A, Rotkopf L. Imagerie du cancer du rein de l’adulte. Rev Prat 1992; 42: 55-59.
[19] Steiner G, Cairns P, Polascik TJ, Marshall F F, Epstein J I, Sidransky D et al. High-density mapping of chromosomal arm 1q in renal collecting duct carcinoma: region of minimal deletion at 1q32.1-32.2. Cancer Res. 1996; 56 (21): 5044-5046.
[20] Chow W H, Devesa S S, Warren J L, Fraumeni Jr J F. Rising incidence of renal cell cancer in United States. JAMA 1999; 281 (17): 1628-1631.
[21] Lightfoot N, Conlon M, Kreiger N, Bissett R, Desai M, Warde P et al. Impact of non-invasive imaging on increased inci- dental detection of renal cell cancer. Eur Urol 2000; 37: 521-527.
[22] Bensalah K, Albiges L, Bernhard J C, Bigot P, Bodin T, Boissier R et al. Retracted: Recommandations françaises du Comité de Cancérologie de l’AFU – Actualisation 2018–2020: prise en charge du cancer du rein. Prog Urol. 2018; 28 (12): S3-31.
[23] Lecouteux A, Rigaud J, Glemain P, Le Normand L, Bouchot O, Karam G. Néphrectomie partielle de nécessité pour carcinome à cellules rénales: résultats oncologiques et fonctionnels. Prog urol. 2011; 21: 599-606.
[24] Springer C, Hoda M R, Fajkovic H, Pini G, Mohammed N, Fornara P et al. Laparoscopic vs open partial nephrectomy for T1 renal tumours: evaluation of long- term oncological and functional outcomes in 340 patients. BJU Int. 2013; 111: 281-288.
[25] Miller J C, Pien H H, Sahani D, Sorensen A G, Thrall J H. Imaging angiogenesis: applications and potential for drug development. J Natl Cancer Inst 2005; 97: 172-187.
[26] Rini B I, Garcia J, Elson P, Wood L, Shah S, Stephenson A et al. The Effect of Sunitinib on Primary Renal Cell Carcinoma and Facilitation of Subsequent Surgery. Journal of Urology. 2012; 187 (5): 1548-1554.
[27] Silberstein J L, Millard F, Mehrazin R, Kopp R, Bazzi W, DiBlasio C J et al. Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery: FEASIBILITY AND EFFICACY OF NEOADJUVANT SUNITINIB BEFORE NEPHRON-SPARING SURGERY. BJU International. 2010; 106 (9): 1270-1276.
[28] Karakiewicz P I, Suardi N, Jeldres C, Audet P, Ghosn P, Patard J J et al. Neoadjuvant Sutent Induction Therapy May Effectively Down-Stage Renal Cell Carcinoma Atrial Thrombi. Eur Urol. 2008; 53 (4): 845848.
[29] Huang D, Ding Y, Li Y, Luo W M, Zhang Z F, Snider J et al. Sunitinib Acts Primarily on Tumor Endothelium rather than Tumor Cells to Inhibit the Growth of Renal Cell Carcinoma. Cancer Research. 2010; 70 (3): 1053-1062.
[30] Khafaja S, Kourie HR, Matar D, Sader-Ghorra C, Kattan J. Kidney Cancer in Lebanon: a Specific Histological Distribution? Asian Pacific Journal of Cancer Prevention. 2015; 16 (1): 363365.
[31] Bernhard J C, Pantuck AJ, Wallerand H, Crepel M, Ferrière J M, Bellec L, et al. Predictive factors foripsi lateral recurrence after nephron-sparing surgery in renal cell carcinoma. Eur Urol 2010; 57: 1080—1086.
[32] Antonelli A, Cozzoli A, Zani D, Zanotelli T, Nicolai M, Cunico SC, et al. The follow-up management of non-metastatic renal cell carcinoma: definition of a surveillance protocol. BJU Int 2007; 99: 296—300.
Cite This Article
  • APA Style

    Modou Ndiaye, Abdoulaye Ndiath, Babacar Sine, Alioune Sarr, Ousmane Sow, et al. (2020). Kidney Tumors in Adult: Epidemiological, Clinical, Histopathological, Therapeutic and Progressive Aspects. International Journal of Clinical Urology, 4(2), 39-44. https://doi.org/10.11648/j.ijcu.20200402.11

    Copy | Download

    ACS Style

    Modou Ndiaye; Abdoulaye Ndiath; Babacar Sine; Alioune Sarr; Ousmane Sow, et al. Kidney Tumors in Adult: Epidemiological, Clinical, Histopathological, Therapeutic and Progressive Aspects. Int. J. Clin. Urol. 2020, 4(2), 39-44. doi: 10.11648/j.ijcu.20200402.11

    Copy | Download

    AMA Style

    Modou Ndiaye, Abdoulaye Ndiath, Babacar Sine, Alioune Sarr, Ousmane Sow, et al. Kidney Tumors in Adult: Epidemiological, Clinical, Histopathological, Therapeutic and Progressive Aspects. Int J Clin Urol. 2020;4(2):39-44. doi: 10.11648/j.ijcu.20200402.11

    Copy | Download

  • @article{10.11648/j.ijcu.20200402.11,
      author = {Modou Ndiaye and Abdoulaye Ndiath and Babacar Sine and Alioune Sarr and Ousmane Sow and Omar Gaye and Ndiaga Seck Ndour and Aboubacar Traoré and Cyrille Zé Ondo and Amath Thiam and Ngor Mack Thiam and El Hadji Malick Diaw and Ousmane Dabo and Boubacar Fall and Babacar Diao and Papa Ahmed Fall and Alain Khassim Ndoye},
      title = {Kidney Tumors in Adult: Epidemiological, Clinical, Histopathological, Therapeutic and Progressive Aspects},
      journal = {International Journal of Clinical Urology},
      volume = {4},
      number = {2},
      pages = {39-44},
      doi = {10.11648/j.ijcu.20200402.11},
      url = {https://doi.org/10.11648/j.ijcu.20200402.11},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcu.20200402.11},
      abstract = {Objective: To study the epidemiological, diagnostic and therapeutic profile of kidney tumors in adults over the past five years. Patients and methods: This was a retrospective, descriptive and analytical Study from the 1st of January 2014 to 31st of December 2018. All patients aged 18 years or older hospitalized, followed or operated in the service for a kidney tumor were included in the serie. The parameters studied were: epidemiological, clinical and paraclinical aspects, TNM stage (2017), treatment, histological type, evolution and survival. The calculation of survival rate was done with SPSS IBM statistics 24. Results: sixty-seven patients were included. The average annual incidence was 13. The average age of the patients was 49.6±15.6 years. The sex-ratio was 1.2. Hypertension, smoking and obesity were the main risk factors found. The average size of the tumor was 7.7±4.40 cm. The left kidney location was more frequent. Thirteen patients (20%) had a localized tumor in the kidney, twenty patients (31%) had locally advanced cancer and thirty two patients (49%) had metastasized cancer. Forty-seven patients (70%) had surgical treatment, including five patients with an anti-angiogenic adjuvant therapy. Twelve (17.9%) patients had an anti-angiogenic therapy only. Clear cell carcinoma was the most common histology type. The overall survival (OS) rate for cancer patients at 2 years was 22% for surgical treatment, 8% for medical treatment. Conclusion: this work reveals that adult kidney cancer affects young adult and is discovered at advanced stages without any significant change in the epidemiological and clinical profile of these cancers during the two decades.},
     year = {2020}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Kidney Tumors in Adult: Epidemiological, Clinical, Histopathological, Therapeutic and Progressive Aspects
    AU  - Modou Ndiaye
    AU  - Abdoulaye Ndiath
    AU  - Babacar Sine
    AU  - Alioune Sarr
    AU  - Ousmane Sow
    AU  - Omar Gaye
    AU  - Ndiaga Seck Ndour
    AU  - Aboubacar Traoré
    AU  - Cyrille Zé Ondo
    AU  - Amath Thiam
    AU  - Ngor Mack Thiam
    AU  - El Hadji Malick Diaw
    AU  - Ousmane Dabo
    AU  - Boubacar Fall
    AU  - Babacar Diao
    AU  - Papa Ahmed Fall
    AU  - Alain Khassim Ndoye
    Y1  - 2020/06/08
    PY  - 2020
    N1  - https://doi.org/10.11648/j.ijcu.20200402.11
    DO  - 10.11648/j.ijcu.20200402.11
    T2  - International Journal of Clinical Urology
    JF  - International Journal of Clinical Urology
    JO  - International Journal of Clinical Urology
    SP  - 39
    EP  - 44
    PB  - Science Publishing Group
    SN  - 2640-1355
    UR  - https://doi.org/10.11648/j.ijcu.20200402.11
    AB  - Objective: To study the epidemiological, diagnostic and therapeutic profile of kidney tumors in adults over the past five years. Patients and methods: This was a retrospective, descriptive and analytical Study from the 1st of January 2014 to 31st of December 2018. All patients aged 18 years or older hospitalized, followed or operated in the service for a kidney tumor were included in the serie. The parameters studied were: epidemiological, clinical and paraclinical aspects, TNM stage (2017), treatment, histological type, evolution and survival. The calculation of survival rate was done with SPSS IBM statistics 24. Results: sixty-seven patients were included. The average annual incidence was 13. The average age of the patients was 49.6±15.6 years. The sex-ratio was 1.2. Hypertension, smoking and obesity were the main risk factors found. The average size of the tumor was 7.7±4.40 cm. The left kidney location was more frequent. Thirteen patients (20%) had a localized tumor in the kidney, twenty patients (31%) had locally advanced cancer and thirty two patients (49%) had metastasized cancer. Forty-seven patients (70%) had surgical treatment, including five patients with an anti-angiogenic adjuvant therapy. Twelve (17.9%) patients had an anti-angiogenic therapy only. Clear cell carcinoma was the most common histology type. The overall survival (OS) rate for cancer patients at 2 years was 22% for surgical treatment, 8% for medical treatment. Conclusion: this work reveals that adult kidney cancer affects young adult and is discovered at advanced stages without any significant change in the epidemiological and clinical profile of these cancers during the two decades.
    VL  - 4
    IS  - 2
    ER  - 

    Copy | Download

Author Information
  • Urology-Andrology Department, Aristide Le Dantec Hospital, Dakar, Senegal

  • Urology-Andrology Department, Aristide Le Dantec Hospital, Dakar, Senegal

  • Urology-Andrology Department, Aristide Le Dantec Hospital, Dakar, Senegal

  • Urology-Andrology Department, Aristide Le Dantec Hospital, Dakar, Senegal

  • Urology-Andrology Department, Aristide Le Dantec Hospital, Dakar, Senegal

  • Urology-Andrology Department, Idrissa Pouye Hospital, Dakar, Senegal

  • Urology-Andrology Department, Aristide Le Dantec Hospital, Dakar, Senegal

  • Urology-Andrology Department, De la Paix Hospital, Ziguinchor, Senegal

  • Urology-Andrology Department, Aristide Le Dantec Hospital, Dakar, Senegal

  • Urology-Andrology Department, Aristide Le Dantec Hospital, Dakar, Senegal

  • Urology-Andrology Department, Idrissa Pouye Hospital, Dakar, Senegal

  • Urology-Andrology Department, Aristide Le Dantec Hospital, Dakar, Senegal

  • Urology-Andrology Department, Idrissa Pouye Hospital, Dakar, Senegal

  • Urology-Andrology Department, De la Paix Hospital, Ziguinchor, Senegal

  • Urology-Andrology Department, Aristide Le Dantec Hospital, Dakar, Senegal

  • Urology-Andrology Department, Dala Diam Hospital, Dakar, Senegal

  • Urology-Andrology Department, Aristide Le Dantec Hospital, Dakar, Senegal

  • Sections